Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Safety in iron management.

Steven Fishbane1

  • 1Winthrop-University Hospital, Mineola, NY 11501, USA. sfishbane@winthrop.org

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|May 31, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

KDOQI US Commentary on the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in CKD.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

Correction to: Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.

Kidney360·2026
Same author

Composite Primary Outcomes in Nephrology Clinical Trials.

Kidney medicine·2026
Same author

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.

The New England journal of medicine·2026
Same author

Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD).

Kidney international·2026
Same author

Influence of Concomitant Opioids on Difelikefalin Treatment Outcomes in Adults with Moderate-to-Severe Pruritus on Maintenance Hemodialysis: Exploratory Analyses.

Kidney & blood pressure research·2025
Same journal

Approach to Hyperkalemia: The Role of Diet and Pharmacological Therapies.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

High Protein Diets: What to Tell Our Patients.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Progressive Kidney Dysfunction and Ocular Clues: A Quiz.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Influence of Lactate Dehydrogenase on the Measurement of Blood Bicarbonate.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Urinary CXCL9 and CXCL10, Interstitial Inflammation and Disease Activity Over Time in Acute Interstitial Nephritis.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Hemophagocytic Lymphohistiocytosis and Fibroblast Growth Factor 23 (FGF23)-Induced Hypophosphatemia.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
See all related articles

Intravenous iron therapy is crucial for hemodialysis patients to maintain hemoglobin levels. Newer iron formulations like sodium ferric gluconate offer improved safety compared to older iron dextran, which has been linked to fatalities.

Area of Science:

  • Nephrology
  • Pharmacology
  • Hematology

Background:

  • Intravenous (IV) iron therapy is essential for managing hemodialysis patients.
  • National Kidney Foundation guidelines recommend regular IV iron to achieve target hemoglobin (Hgb) levels.
  • Three IV iron compounds are available: iron dextran, sodium ferric gluconate, and iron sucrose.

Purpose of the Study:

  • To review and compare the safety profiles of available IV iron therapies.
  • To highlight the risks associated with iron dextran and the improved safety of newer agents.

Main Methods:

  • Review of existing safety data on IV iron compounds.
  • Analysis of prospective safety comparisons, including placebo-controlled studies.
  • Examination of reported adverse events and fatalities linked to IV iron therapies.

Related Experiment Videos

Main Results:

  • All reviewed IV iron compounds effectively increase Hgb/hematocrit levels.
  • Iron dextran has been associated with over 30 deaths in the past two decades.
  • Sodium ferric gluconate and iron sucrose demonstrate more favorable safety profiles.
  • A large prospective study showed sodium ferric gluconate's safety profile similar to placebo for anaphylactoid reactions.

Conclusions:

  • While effective, IV iron therapies differ significantly in safety.
  • Sodium ferric gluconate and iron sucrose represent safer alternatives to iron dextran for hemodialysis patients.
  • Careful consideration of safety data is crucial when selecting IV iron therapy.